Clarify the Role of Monoclonal Antibodies in Treatment of COVID-19
Casirivimab/imdevimab will be the second monoclonal antibody treatment authorized for OUTpatients with COVID-19.
This combo will be an alternative to bamlanivimab as a single-dose IV infusion. And more are in the works.
These "mabs" block SARS-CoV-2 from entering cells.